Stock Track | Telix Pharmaceuticals Soars 5.04% Intraday on FDA Resubmission and Strong Growth Prospects

Stock Track

Mar 20

Telix Pharmaceuticals Ltd (ASX: TLX) saw its shares soar 5.04% during intraday trading on Friday, marking a significant upward movement for the biopharmaceutical company.

The surge follows the company's resubmission of its New Drug Application to the U.S. FDA for TLX101-Px, an imaging agent for glioblastoma, with new data addressing prior feedback and supporting approval. This regulatory progress in a high-need area with limited competition represents a potential major growth driver for the company.

Additionally, Telix recently reported strong financial performance with full-year revenue reaching US$803 million, representing 56% year-on-year growth, and provided optimistic guidance for the current year. The company also benefits from overwhelmingly positive analyst sentiment, with all 16 covering analysts rating the stock as a buy or strong buy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1136813239"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1136813239\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1136813239?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 09:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136813239","market":"nz","top_or_hot":-1,"title":"Stock Track | Telix Pharmaceuticals Soars 5.04% Intraday on FDA Resubmission and Strong Growth Prospects","media":"Stock Track","content":"<p>Telix Pharmaceuticals Ltd (ASX: TLX) saw its shares soar 5.04% during intraday trading on Friday, marking a significant upward movement for the biopharmaceutical company.</p><p>The surge follows the company's resubmission of its New Drug Application to the U.S. FDA for TLX101-Px, an imaging agent for glioblastoma, with new data addressing prior feedback and supporting approval. This regulatory progress in a high-need area with limited competition represents a potential major growth driver for the company.</p><p>Additionally, Telix recently reported strong financial performance with full-year revenue reaching US$803 million, representing 56% year-on-year growth, and provided optimistic guidance for the current year. The company also benefits from overwhelmingly positive analyst sentiment, with all 16 covering analysts rating the stock as a buy or strong buy.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Telix Pharmaceuticals Soars 5.04% Intraday on FDA Resubmission and Strong Growth Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Telix Pharmaceuticals Soars 5.04% Intraday on FDA Resubmission and Strong Growth Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-20 09:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Telix Pharmaceuticals Ltd (ASX: TLX) saw its shares soar 5.04% during intraday trading on Friday, marking a significant upward movement for the biopharmaceutical company.</p><p>The surge follows the company's resubmission of its New Drug Application to the U.S. FDA for TLX101-Px, an imaging agent for glioblastoma, with new data addressing prior feedback and supporting approval. This regulatory progress in a high-need area with limited competition represents a potential major growth driver for the company.</p><p>Additionally, Telix recently reported strong financial performance with full-year revenue reaching US$803 million, representing 56% year-on-year growth, and provided optimistic guidance for the current year. The company also benefits from overwhelmingly positive analyst sentiment, with all 16 covering analysts rating the stock as a buy or strong buy.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLX.AU","symbol_name":"TELIX PHARMACEUTICALS LTD","start_time":0,"source_url":"","article_id":"1136813239","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136813239","pubTimestamp":1773970232,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Telix Pharmaceuticals Ltd (ASX: TLX) saw its shares soar 5.04% during intraday trading on Friday, marking a significant upward movement for the biopharmaceutical company.The surge follows the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLX.AU":"TELIX PHARMACEUTICALS LTD"},"translate_title":"个股追踪|Telix制药盘中大涨5.04%因FDA重新提交且增长前景强劲","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":1},"content_text":"Telix Pharmaceuticals Ltd (ASX: TLX) saw its shares soar 5.04% during intraday trading on Friday, marking a significant upward movement for the biopharmaceutical company.The surge follows the company's resubmission of its New Drug Application to the U.S. FDA for TLX101-Px, an imaging agent for glioblastoma, with new data addressing prior feedback and supporting approval. This regulatory progress in a high-need area with limited competition represents a potential major growth driver for the company.Additionally, Telix recently reported strong financial performance with full-year revenue reaching US$803 million, representing 56% year-on-year growth, and provided optimistic guidance for the current year. The company also benefits from overwhelmingly positive analyst sentiment, with all 16 covering analysts rating the stock as a buy or strong buy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}